|
 |
| home > ebr > spring 2002 > preclinical and clinical evaluation of therapeutic vaccines - 21st-22nd january 2002, london |
|
|
 PUBLICATIONS |
European BioPharmaceutical Review
|
| Since as long ago as the 1890s, when William Coley used streptococcal cultures to treat patients with advanced sarcoma, it has been known that the immune system can be prompted to attack cancer cells. More recently, melanoma tumours in animals have been shown to regress when injected with modified autologous cancer cells primed to stimulate an immune response. And now, somewhat like the resurgence of interest surrounding recent therapeutic success with monoclonal antibodies, the concept of stimulating the immune system to recognise and destroy foreign or indeed tumour cells, so-called 'therapeutic vaccines', is, it seems, again in vogue.This kind of technology is distinct from normal vaccination in that the patient already has the disease or condition before the vaccine is given. For any number of reasons, the patient has not already responded to the disease-associated antigens - possibly because they are 'self'-antigens (on endogenous cells such as tumour cells), or they are hidden from the immune response by directly disrupting or affecting immune cell function (HIV). |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
|
